Download PDF
Exp Clin Endocrinol Diabetes 2009; 117(9): 519-521
DOI: 10.1055/s-0029-1216351
Short Communication

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

The Proline 12 Alanine Substitution in the PPARγ2 Gene is Associated With Increased Extent of Coronary Artery Disease in Men

J. G. Schneider 1 [*] , S. Schiekofer 2 [*] , M. von Eynatten 3 , P. Schlimmer 4 , K. A. Dugi 3
  • 1Department of Medicine, Washington University in St. Louis, USA
  • 2Department of Medicine, Saarland University School of Medicine, Homburg/Saar, Germany
  • 3Department of Medicine I, Ruprecht-Karls-University of Heidelberg, Germany
  • 4Department of Medicine, Saarland University Academic Teaching Hospital at Merzig/Saar, Germany
Further Information

Publication History

received 19.02.2009 first decision 11.03.2009

accepted 11.03.2009

Publication Date:
17 June 2009 (online)

Also available at
    Permissions and Reprints

Abstract

Objective: To determine whether there is an independent association between the Pro12Ala polymorphism in the peroxisome proliferator-activated-receptor γ2 (PPARγ2)-gene and the extent of coronary artery disease in men.

Research Design and Methods: We determined the Pro12Ala polymorphism in the PPARγ2 gene in 240 male patients undergoing elective coronary angiograpy, and quantitated the degree of CAD by evaluating the extent-score which better correlates with known risk factors than other measures of CAD.

Results: The presence of the 12Ala allele was significantly associated with higher CAD extent (r=0.27, p<0.01). CAD extent was also correlated with the extent of insulin resistance (HOMA, r=0.22, p<0.01), and age (r=0.16, p<0.05). Multivariate analysis revealed an independent association between the 12Ala allele PPARγ2 with extent-score (β=0.32, p<0.01).

Conclusions: The 12Ala allele in PPARγ2 correlates with a significantly increased CAD extent in men, which suggest that lower activity of the transcription factor PPARγ2 is associated with more severe CAD.

Key words

coronary artery disease - cardiovascular incidences - coronary syndrome - receptors - signal transduction

References

  • 1 Auwerx J. PPARgamma, the ultimate thrifty gene.  Diabetologia. 1999;  42 1033-1049
    CrossrefPubMedGoogle Scholar
  • 2 Babaev VR, Yancey PG, Ryzhov SV. et al . Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice.  Arterioscler Thromb Vasc Biol. 2005;  25 1647-1653
    CrossrefPubMedGoogle Scholar
  • 3 Deeb SS, Fajas L, Nemoto M. et al . A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.  Nat Genet. 1998;  20 284-287
    CrossrefPubMedGoogle Scholar
  • 4 Doney AS, Fischer B, Leese G. et al . Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study.  Arterioscler Thromb Vasc Biol. 2004;  24 2403-2407
    CrossrefPubMedGoogle Scholar
  • 5 Henderson HE, Kastelein JJ, Zwinderman AH. et al . Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins.  J Lipid Res. 1999;  40 735-743
    PubMedGoogle Scholar
  • 6 Li L, Cheng LX, Nsenga R. et al . Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population.  Clin Cardiol. 2006;  29 300-304
    CrossrefPubMedGoogle Scholar
  • 7 Memisoglu A, Hu FB, Hankinson SE. et al . Prospective study of the association between the proline to alanine codon 12 polymorphism in the PPARgamma gene and type 2 diabetes.  Diabetes Care. 2003;  26 2915-2917
    CrossrefPubMedGoogle Scholar
  • 8 Rhee EJ, Kwon CH, Lee WY. et al . No association of Pro12Ala polymorphism of PPAR-gamma gene with coronary artery disease in Korean subjects.  Circ J. 2007;  71 338-342
    CrossrefPubMedGoogle Scholar
  • 9 Schneider J, Kreuzer J, Hamann A. et al . The proline 12 alanine substitution in the peroxisome proliferator – activated receptor-gamma2 gene is associated with lower lipoprotein lipase activity in vivo.  Diabetes. 2002;  51 867-870
    CrossrefPubMedGoogle Scholar
  • 10 Stumvoll M, Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism.  Diabetes. 2002;  51 2341-2347
    PubMedGoogle Scholar
  • 11 Sullivan DR, Marwick TH, Freedman SB. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors.  Am Heart J. 1990;  119 1262-1267
    CrossrefPubMedGoogle Scholar
  • 12 Temelkova-Kurktschiev T, Hanefeld M, Chinetti G. et al . Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis.  J Clin Endocrinol Metab. 2004;  89 4238-4242
    CrossrefPubMedGoogle Scholar
  • 13 Tontonoz P, Nagy L, Alvarez JG. et al . PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL.  Cell. 1998;  93 241-252
    CrossrefPubMedGoogle Scholar
  • 14 Eynatten M von, Schneider JG, Humpert PM. et al . Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men.  J Am Coll Cardiol. 2006;  47 2124-2126
    CrossrefPubMedGoogle Scholar
  • 15 Zafarmand MH, van der Schouw YT, Grobbee DE. et al . Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: a case-cohort study and meta-analyses.  Vasc Health Risk Manag. 2008;  4 427-436
    PubMedGoogle Scholar

1 Both authors contributed equally

Correspondence

J. G. SchneiderMD 

Washington University School of Medicine

Department of Internal Medicine

Campus Box 8069

St. Louis

MO 63110

USA

Phone: +1/314/454 89 73

Fax: +1/314/454 89 79

Email: js@mailbox-js.de

      >